IP Library Granted Patent US 7,244,865
Granted Patent B2
US 7,244,865 · App. 10/537,965 · Granted Jul 17, 2007

Process for preparing benzhydrylthioacetamide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,244,865
App. No.
10/537,965
Granted
Jul 17, 2007
Kind
B2
Abstract

The present invention is directed to an improved process for preparing modafinil wherein benzhydrylthioacetamide is prepared in high yield and purity by the reaction of a haloacetamide with the reaction product of thiourea and benzhydrol in aqueous solution. The reaction employing the haloacetamide is conducted in a solvent comprising water and an organic solvent such as dimethylformamide having dissolved therein a basic salt such as potassium carbonate. The resulting benzhydrylthioacetamide can be oxidized to provide the pharmaceutical modafinil.

Claims (36)

1. A process for the preparing of benzhydrylthioacetamide comprising reacting benzhydrylthiocarboxamidine salt with haloacetamide in a reaction medium comprising water, a water miscible organic solvent and a water soluble basic salt selected from the group consisting of alkali metal and alkaline earth metal sulfates, sulfides, phosphates, carbonates, bicarbonates, nitrates, phosphates and phosphinates.

2. The process of claim 1 wherein the haloacetamide is chloroacetamide.

3. The process of claim 1 wherein the basic salt is a potassium salt.

4. The process of claim 3 wherein the basic salt is a potassium carbonate salt.

5. The process of claim 1 wherein the basic salt is present in a weight ratio to benzhydrylthiocarboxamidine salt of from about 41 to about 200.

6. The process of claim 5 wherein the basic salt is present in the weight ratio of from about 82 to about 110.

7. The process of claim 5 wherein the basic salt is present in the weight ratio of about 105.

8. The process of claim 1 wherein the volume ratio of water miscible organic solvent to water is in the range of from about 9/1 to 1/9.

9. The process of claim 8 wherein the volume ratio of water miscible organic solvent to water is in the range of from about 2/1 to 1/1.

10. The process of claim 8 wherein the volume ratio of water miscible organic solvent to water is about 3/2.

11. The process of claim 1 wherein the water miscible organic solvent is selected from the group consisting of lower alkanols, acetone and dimethylformamide.

12. The process of claim 11 wherein the lower alkanol is selected from the group consisting of methanol, ethanol, butanol, sec-butyl alcohol, and tert-butyl alcohol.

13. In a process for preparing modafinil comprising the following steps:

reacting benzhydrol with thiourea in the presence of hydrogen bromide to provide benzhydrylthiocarboxamidine bromide;

reacting haloacetamide with the product of step a) to provide benzhydrylthioacetamide;

oxidizing the product of step b) to obtain benzhydrylsulphinylacetamide; and

the improvement which comprises conducting the reaction of step b) in a solvent comprising a water miscible organic solvent, and water in the presence of a basic salt selected from the group consisting of alkali metal and alkaline earth metal sulfates, sulfides, phosphates, carbonates, bicarbonates, nitrates, phosphates and phosphinates.

14. The process of claim 13 wherein the haloacetamide is chloroacetamide.

15. The process of claim 13 wherein the basic salt is a potassium salt.

16. The process of claim 15 wherein the basic salt is a potassium carbonate salt.

17. The process of claim 13 wherein the basic salt is present in a weight ratio to benzhydrylthiocarboxamidine salt of from about 41 to about 200.

18. The process of claim 17 wherein the basic salt is present in the weight ratio of from about 82 to about 110.

19. The process of claim 18 wherein the basic salt is present in the weight ratio of about 105.

20. The process of claim 13 wherein the volume ratio of water miscible organic solvent to water is in the range of from about 9/1 to 1/9.

21. The process of claim 20 wherein the volume ratio of water miscible organic solvent to water is in the range of from about 2/1 to 1/1.

22. The process of claim 20 wherein the volume ratio of water miscible organic solvent to water is about 3/2.

23. The process of claim 13 wherein the water miscible organic solvent is selected from the group consisting of lower alkanols, acetone and dimethylformamide.

24. A process for the purification of modafinil which comprises contacting the crude modafinil with a halo-organic solvent and then separating the modafinil from the solvent.

25. The process of claim 24 wherein the temperature of the mixture of modafinil and halo-organic solvent is raised to a reflux temperature.

26. The process of claim 25 wherein the reflux temperature is maintained for about 30 minutes.

27. The process of claim 24 wherein the halo-organic solvent is selected from the group consisting of chloroform, dichloromethane, and dichloroethane.

28. The process of claim 24 further including the step of adding an aliphatic solvent to the mixture.

29. The process of claim 28 wherein an aliphatic solvent is added to modafinil prior to contacting the modafinil with the halo-organic solvent and the temperature of the mixture is raised to the reflux temperature.

30. The process of claim 29 wherein the reflux temperature is maintained for about 30 minutes.

31. The process of claim 29 wherein the aliphatic solvent is selected from the group consisting of pentane, hexane, heptane and octane.

32. The process of claim 28 wherein the halo-organic solvent is chloroform and the aliphatic solvent is heptane.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →